Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
CC transcript
Auditor change
Employment agrmnt
Oncotelic Therapeutics, Inc. (MATN) Create: Alert

All | News | Filings
Date FiledTypeDescription
11/10/2015 8-K Quarterly results
Docs: "OXIGENE REPORTS THIRD QUARTER 2015 FINANCIAL RESULTS",
"OXIGENE REPORTS THIRD QUARTER 2015 FINANCIAL RESULTS"
08/04/2015 8-K Quarterly results
Docs: "OXIGENE REPORTS SECOND QUARTER 2015 FINANCIAL RESULTS"
04/30/2015 8-K Quarterly results
Docs: "OXiGENE Reports First Quarter 2015 Financial Results Strengthened Cash Position; Fosbretabulin and OXi4503 Clinical Programs Advancing"
11/12/2014 8-K Quarterly results
Docs: "OXiGENE Reports Third Quarter 2014 Financial Results - Positive Data from the Phase 2 GOG 186I Study in Ovarian Cancer Presented at Major Conference -"
08/05/2014 8-K Quarterly results
Docs: "OXiGENE Reports Second Quarter 2014 Financial Results - Phase 2 Trial of Fosbretabulin in Gastrointestinal Neuroendocrine Tumors Planned - - Further Data from Gynecologic Oncology Group Phase 2 Ovarian Cancer Trial to be Presented in November -"
05/06/2014 8-K Quarterly results
Docs: "OXiGENE Reports First Quarter 2014 Financial Results Company Strengthens Cash Position by $20 Million Announced Positive Phase 2 Data in Recurrent Ovarian Cancer for ZYBRESTAT® in Combination With Avastin®"
11/12/2013 8-K Form 8-K - Current report
08/06/2013 8-K Form 8-K - Current report
05/06/2013 8-K Quarterly results
Docs: "OXiGENE Reports First Quarter 2013 Financial Results"
11/08/2012 8-K Quarterly results
Docs: "OXiGENE Reports Third Quarter 2012 Financial Results"
08/08/2012 8-K Form 8-K - Current report
05/09/2012 8-K Quarterly results
Docs: "OXiGENE Reports First Quarter 2012 Financial Results"
11/09/2011 8-K Form 8-K - Current report
08/10/2011 8-K Form 8-K - Current report
05/12/2011 8-K Form 8-K - Current report
03/03/2011 8-K Quarterly results
Docs: "OXiGENE Reports Full Year 2010 Financial Results SOUTH SAN FRANCISCO, Calif., March 3, 2011 — OXiGENE, Inc. a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, reported financial results for the year ending December 31, 2010. The Company also provided an update on recent clinical and corporate progress and outlook for 2011. Financial Results For the year ended December 31, 2010, the consolidated net loss was $23.8 million, compared with a consolidated net loss of $28.9 million for 2009. The consolidated net loss for the year ended December 31, 2010 was impacted primarily by a reduction in operating expenses of approximately $12.7 million, offset by an $8.2 million fluctuation in the gain from the change in fair value of warrants and o..."
11/04/2010 8-K Form 8-K - Current report
08/13/2010 8-K Form 8-K - Current report
05/11/2010 8-K Form 8-K - Current report
02/25/2010 8-K Form 8-K - Current report
11/09/2009 8-K Form 8-K - Current report
07/30/2009 8-K Form 8-K - Current report
05/11/2009 8-K Form 8-K - Current report
03/19/2009 8-K Form 8-K - Current report
11/05/2008 8-K Form 8-K - Current report
08/04/2008 8-K Form 8-K - Current report
05/05/2008 8-K Form 8-K - Current report
02/28/2008 8-K Form 8-K - Current report
11/01/2007 8-K Form 8-K - Current report
07/25/2007 8-K Form 8-K - Current report
04/25/2007 8-K Form 8-K - Current report
03/06/2007 8-K Form 8-K - Current report
10/25/2006 8-K Form 8-K - Current report
07/26/2006 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy